Orphan drug development remains a specialised segment with limited players
A Shifting Landscape – The outsourcing model is here to stay
Demand strong for R&D_mfg services says Syngene COO
Driven by big pharma needs, Syngene to focus on expanding breadth of services & capabilities
Seeing Good Demand for Chemistry, Biology
Syngene interview in 2022 edition of USA Life Sciences report
Syngene to approach regulators for Mangalore unit audit in 12-18 months
As startups mushroom in drug R&D, Syngene builds CRO muscle
Biologics Testing Highlights Need for Analytical Skills
We are co-innovating with global pharma companies – Syngene MD & CEO
